echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > International Chemical > Issue 21/2021 - The chemical giant's third quarter results at a glance

    Issue 21/2021 - The chemical giant's third quarter results at a glance

    • Last Update: 2022-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BASF's sales in the third quarter were €19.
    7 billion, up €5.
    9 billion year-on-year.
    EBIT before special items amounted to €1.
    9 billion, up €1.
    3 billion compared with the prior-year quarter.
    Special items in EBIT amounted to minus €43 million; EBIT amounted to €1.
    8 billion, up significantly from negative €2.
    6 billion in the prior-year quarter.
    EBITDA before special items increased €1.
    2 billion to €2.
    8 billion, and EBITDA was €2.
    7 billion, up €1.
    7 billion year-on-year.
    Net income was €1.
    3 billion, €3.
    4 billion higher than the prior-year quarter, earnings per share were €1.
    36, cash flow from operating activities was €1.
    9 billion, down €204 million from the prior-year quarter, and free cash flow was €1.
    1 billion, down €287 million
    from the prior-year quarter.



    Dow reported third-quarter GAAP earnings per share of $2.
    23 and operating earnings per share of $2.
    75, compared to $0.
    50 in the year-ago quarter, and net sales of $14.
    8 billion, up 53% year-over-year and 7% sequentially.
    Local prices increased by 50% year-on-year and 5% month-on-month; Volume increased 2% year-over-year and 2% sequentially.
    Equity income was $249 million, up $189 million, GAAP net income was $1.
    7 billion, operating EBIT was $2.
    9 billion, up more than $2.
    1 billion, cash from operating activities (i.
    e.
    , continuing operations) was $2.
    7 billion, up $958 million, or $698 million sequentially, free cash flow was $2.
    3 billion, total debt decreased by more than $1.
    1 billion, and overall return to shareholders was $918 million, including dividend returns of $518 million , share buybacks of $400 million
    .



    Celanese earned $4.
    67 per diluted GAAP in the third quarter.
    Adjusted earnings per share were $4.
    82, net sales were a record $2,266 million, including engineering materials second-quarter net sales of $684 million, acetyl chain net sales of $1.
    5 billion, acetate tow net sales of $128 million, operating cash flow of record $630 million, free cash flow of record $520 million, capital expenditures of $102 million, cash returns to shareholders of $376 million, including $300 million in share repurchases and $76 million in dividends, and an effective GAAP tax rate of 16 %, 12%
    in the same period last year.



    Air Liquide's total Group revenue in the third quarter was 5.
    834 billion euros, up 17.
    2% year-on-year, continuing the growth trend
    in the first half of the year.
    Among them, gas and services revenue was 5.
    585 billion euros, a year-on-year increase of 16.
    9%; Engineering and manufacturing revenue was EUR 81 million, up 36.
    9% year-on-year; Global market and technology revenues increased by 15.
    9 percent
    to €168 million.



    LG Chem sales in the third quarter were $9.
    16 billion, up 41.
    4% year-on-year; Operating profit was USD 630 million, down 19.
    6%
    year-over-year.
    Among them, the third-quarter results of each business area were: petrochemical sales of USD 4.
    86 billion and operating profit of USD 940 million, advanced materials sales of USD 1 billion and operating profit of USD 40 million, life sciences sales of USD 150 million and operating profit of USD 100 million, LG Energy Solution sales of USD 3.
    48 billion and operating profit of -USD 320 million, and Farm Hannon sales of USD 110 million and operating profit of USD 100



    Clariant's sales from continuing operations increased by 23 percent to CHF 1,096 million in the third quarter; EBITDA increased by 41.
    7 percent year-on-year to CHF 1.
    8 million.
    The margin was 16.
    4%, compared to 14.
    2%
    in the same period last year.
    In each segment, sales of catalysts increased by 5% to CHF 216 million and EBITDA margin of 12%; Care Chemicals sales increased by 31 percent to CHF 436 million and an EBITDA margin of 22.
    2 percent; Natural resources sales increased by 25 percent to CHF 444 million and the EBITDA margin was 17.
    6 percent
    .



    Group sales in the third quarter were €1,658.
    6 million, up 40 percent year-on-year and 11 percent sequentially.
    EBITDA was €433.
    7 million, more than twice as much as the same period last year, up 33% sequentially, with an EBITDA margin of 26.
    1%, compared to 16.
    1% in the prior-year period and 21.
    8% in the previous quarter; EBIT was €342.
    6 million, more than three times that of the prior-year period, with an EBIT margin of 20.
    7 percent.
    Net income was EUR 248.
    7 million and net income per share was EUR
    4.
    90.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.